Gyrablock (Norfloxacin)

Gyrablock is prescribed for bacterial infections where norfloxacin is considered an appropriate therapy.

• Uncomplicated urinary tract infections caused by susceptible Gram‑negative organisms.
• Acute bacterial prostatitis when oral therapy is indicated.
• Traveler’s diarrhea or dysentery due to susceptible enteric pathogens.
• Gonococcal infections of the urethra, cervix, or rectum when alternative agents are unsuitable.
• Certain lower respiratory tract infections, such as acute exacerbations of chronic bronchitis, caused by susceptible strains.
• Skin and soft‑tissue infections caused by susceptible organisms.
• Typhoid fever caused by susceptible Salmonella Typhi.

The safety profile of Gyrablock reflects the known adverse effects of oral norfloxacin, which can vary in frequency and severity.

Common

• Nausea or general stomach discomfort.
• Diarrhea, often watery and may be accompanied by cramping.
• Headache, varying from mild to moderate intensity.
• Dizziness or a sensation of light‑headedness.

Serious

• Tendon inflammation or rupture, especially of the Achilles tendon.
• Peripheral neuropathy presenting as tingling, numbness, or burning sensations.
• Prolongation of the QT interval on electrocardiogram, increasing arrhythmia risk.
• Severe allergic reactions such as anaphylaxis, angioedema, or Stevens‑Johnson syndrome.

Before prescribing Gyrablock, clinicians should evaluate patient‑specific factors and known safety considerations.

• Do not use in patients with a known hypersensitivity to norfloxacin or other fluoroquinolones.
• Use with caution in pregnant or breastfeeding individuals; safety data are limited.
• Adjust dosing in patients with significant renal impairment.
• Avoid in patients with a history of tendon disorders or recent corticosteroid therapy.
• Monitor cardiac function in individuals with known QT‑interval prolongation.
• Use cautiously in children and adolescents, as safety has not been established.

Norfloxacin can affect the pharmacokinetics of several medicines; some combinations should be avoided while others require monitoring.

Avoid

• Antacids or mineral supplements containing magnesium, aluminum, calcium, or iron, which can reduce norfloxacin absorption.
• Warfarin, because norfloxacin may increase INR and bleeding risk.
• Theophylline, as norfloxacin can raise serum theophylline concentrations.

Use with caution

• Drugs that prolong the QT interval (e.g., certain antiarrhythmics, antipsychotics) may increase cardiac risk.
• Diabetic agents, since norfloxacin can cause abnormal blood‑glucose levels.
• Corticosteroids, due to an elevated risk of tendon rupture when combined with fluoroquinolones.